ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MLR Maelor

100.00
0.00 (0.00%)
27 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maelor LSE:MLR London Ordinary Share GB00B2QBY649 ORD 70P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 100.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Schedule 1 - Maelor plc

10/04/2007 12:11pm

UK Regulatory


RNS Number:5886U
AIM
10 April 2007


 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR
                                             COMPANIES ("AIM RULES")

COMPANY NAME: Maelor plc

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :


Office Village,

Chester Business Park,

Chester CH4 9QZ

COUNTRY OF INCORPORATION: United Kingdom

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: www.maelor.plc.uk

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
STATED:



Company business

Maelor is a specialist pharmaceuticals and medical devices company, focused in the critical care market. The
Company has expertise in developing and commercialising both pharmaceuticals and medical devices. The new
management team is committed to delivering the vision of establishing a significant business in specialist
hospital medicine, initially focused in the critical care sector. This vision will be realised through aggressive
acquisition, development and organic growth of late stage and launched products, to rapidly drive turnover and
profit.



Main Country of Operation

United Kingdom



Admission is sought in connection with a reverse take-over under Rule 14

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where
known, number and type of shares, nominal value and issue price to which it seeks admission and the number and
type to be held as treasury shares):



Re-Admission Existing Ordinary Shares of 10p each             34,280,833

New Ordinary shares of 10p each (at an issue price of10p)     90,000,000

Total number of Ordinary shares                              124,280,833



CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

fundraising #8 million, #12.4 million market capitalisation

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

10.5% (Directors and Vendors)

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE
COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

not applicable / none

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known
or including any other name by which each is known):

John Gregory / Non-Executive Director

Tim Wright / Chief Executive Officer

Geoff McMillan / Non-Executive Chairman

Peter Murray / Non-Executive Director

Ann Hardy / Operations Director

Nigel Goldsmith / Finance Director


FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE
AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each
is known):


Significant Shareholders before Admission
                                                   As at date of this document
                                             No. of Ordinary Shares   % of issued share
                                                                                capital

Chase Nominees Limited                                    6,124,812               17.9%
Barclayshare Nominees Limited                             2,839,876                8.3%
TD Waterhouse Nominees (Europe)                           2,518,495                7.3%
Capita Trust Company Limited                              1,404,296                4.1%
HSDL Nominees Limited                                     1,061,877                3.1%



Significant Shareholders after Admission
                                                As at date of this       Immediately following the
                                                     document          Acquisition, the Placing and
                                                                                 Admission
                                                  No. of   % of issued  No. of Ordinary  % of issued
                                                Ordinary share capital           Shares        share
                                                  Shares                                     capital

State Street Nominees Limited                          -             -       11,200,000         9.0%
MD Barnard & Co Limited                                -             -       10,000,000         8.0%
HSBC Nominees Limited                                  -             -        6,500,000         5.2%
Chase Nominees Limited1                        6,123,812         17.9%        6,123,812         4.9%
Brewin Nominees Limited                                -             -        6,000,000         4.8%
JP Morgan Chase Nominees Limited 1                     -             -        5,000,000         4.0%
Pershing Keen Nominees Limited                         -             -        4,900,000         3.9%
Heartwood Nominees Limited2                            -             -        3,200,000         2.6%
Barclayshare Nominees Limited                  2,839,876          8.3%        2,839,876         2.3%
TD Waterhouse Nominees (Europe) Limited        2,518,495          7.3%        2,518,495         2.0%
Capita Trust Company Limited2                  1,404,296          4.1%        1,404,296         1.1%
HSDL Nominees Limited                          1,061,877          3.1%        1,061,877         0.9%



1 held as nominee for Bluehone Investors LLP

2 held as nominee for Close Investments Limited



NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:



none



(i)                  ANTICIPATED ACCOUNTING REFERENCE DATE 31 March

(ii)                DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED: 30
September 2006

(iii)               DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

30 September 2007, 30 December 2007, 30 September 2008

EXPECTED ADMISSION DATE:

First Admission on 8 May 2007 in relation to 70,005,833 Existing Ordinary and New VCT/EIS Shares



Second Admission on 9 May 2007 in relation to 44,275,000 Protected VCT and Non-VCT Shares



Third Admission on 10 May 2007 in relation to 10,000,000 Consideration Shares



NAME AND ADDRESS OF NOMINATED ADVISER:

Noble & Company Limited

120 Old Broad Street

London EC2N 1AR

NAME AND ADDRESS OF BROKER:

Noble & Company Limited

120 Old Broad Street

London EC2N 1AR



Lewis Charles Securities Ltd

4 - 7 Chiswell Street

London EC1Y 4UP

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION
DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE
ADMISSION OF ITS SECURITIES:

Noble & Company Limited

120 Old Broad Street

London

EC2N 1AR

DATE OF NOTIFICATION: 10 April 2007

NEW/ UPDATE: NEW



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PAABBGDSGBBGGRG

1 Year Maelor Chart

1 Year Maelor Chart

1 Month Maelor Chart

1 Month Maelor Chart